A large number of controversies about the management of breast cancer produce uncertainties for patients and physicians alike. In addition, questions are constantly raised about the true value of new approaches or treatments.
Methods
The authors have conducted a critical review of the literature on several of these issues, and they present a balanced view that can be useful for clinical decision making.
Results
Although new staging systems for ductal carcinoma in situ have been proposed, a consensus has not yet been reached regarding the criteria to allow tumor excision alone. The extent of benefit of the main adjuvant therapies is becoming better established, and improvement in outcomes may accrue from dose-intensive treatments and autologous stem cell or hematopoietic growth factor support.
Conclusions
Progress in breast cancer management continues to evolve. Several new approaches either reduce morbidity or improve outcomes.
Get full access to this article
View all access options for this article.
References
1.
ErnsterV.L., BarclayJ., KerlikowskeK.Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA.1996; 275: 913–918.
2.
PageD.L., LagiosM.D.Pathologic analysis of the National Surgical Adjuvant Breast Project (NSABP) B-17 Trial. Cancer.1995; 75: 1219–1222.
3.
LagiosM.D., MargolinF.R., WestdahlP.R.Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer.1989; 63: 618–624.
4.
SimpsonJ.F., PageD.L.The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer. Semin Oncol.1996; 23: 428–435.
5.
SilversteinM.J., PollerD.N., WaismanJ.R.Prognostic classification of breast ductal carcinoma-in-situ. Lancet.1995; 345: 1154–1157.
6.
FisherB., CostantinoJ., RedmondC.Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med.1993; 328: 1581–1586.
7.
PageD.L., LagiosM.D.Pathologic analysis of the National Surgical Adjuvant Breast Project (NSABP) B-17 Trial: unanswered questions remaining unanswered considering current concepts of ductal carcinoma in situ. Cancer.1995; 75: 1219–1222.
8.
SolinL.J., SchultzD.J., FowbleB.L.Ten-year results of the treatment of early-stage breast carcinoma in elderly women using breast-conserving surgery and definitive breast irradiation. Int J Radiat Oncol Biol Phys.1995; 33: 45–51.
9.
ReintgenD., JosephE., LymanG.H.The role of selective lymphadenectomy in breast cancer. Cancer Cont: JMCC.1997; 4: 211–219.
10.
SmallW.Jr, MorrowM.Local management of primary breast cancer. Cancer Cont: JMCC.1997; 4: 201–210.
11.
GreenbergH.Conservation therapy of the breast: optimizing long-term results. Cancer Cont: JMCC.1997; 4: 220–225.
12.
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women.Early Breast Cancer Trialists’ Collaborative Group. Lancet.1992; 339: 1–15, 71–85.
13.
MoxleyJH3d, AllegraJ.C., HenneyJ.Treatment of primary breast cancer: summary of the National Institutes of Health Consensus Development Conference. JAMA.1980; 244: 797–800.
14.
Consensus conference.Adjuvant chemotherapy for breast cancer. JAMA.1985; 254: 3461–3463.
15.
NIH Consensus Development Conference statement on the treatment of early-stage breast cancer. Oncology (Huntingt).1991; 5: 120–124.
16.
Adjuvant therapy of breast cancer: tamoxifen update.Bethesda, MD: National Cancer Institute; November 30, 1995.
17.
BonadonnaG., BrusamolinoE., ValagussaP.Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med.1976; 294: 405–410.
18.
CummingsF.J., GelmanR., HortonJ.Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol.1985; 3: 932–940.
19.
TormeyD.C., WeinbergV.E., LeoneL.A.A comparison of intermittent vs. continuous and of andriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer: a Cancer and Leukemia Group B study. Am J Clin Oncol.1984; 7: 231–239.
20.
MissetJ.L., di PalmaM., DelgadoM.Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol.1996; 14: 1136–1145.
21.
CarpenterJ.T., Velez-GarciaE., AronB.S.Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (adriamycin) and fluorouracil (CAF) vs cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer. Proc Annu Meet Am Soc Clin Oncol.1994; 13: A68.
22.
BonadonnaG., ZambettiM., ValagussaP.Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA.1995; 273: 542–547.
23.
PazdurR., KudelkaA.P., KavanaghJ.J.The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev.1993; 19: 351–386.
24.
GianniL., MunzoneE., CapriG.Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol.1995; 13: 2688–2699.
25.
WoodW.C., BudmanD.R., KorzunA.H.Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med.1994; 330: 1253–1259.
26.
HryniukW., LevineM.N.Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol.1986; 4: 1162–1170.
27.
AylesworthC.A., DiehlL.F.High-dose chemotherapy for breast cancer: effective therapy or selection bias?Semin Oncol.1996; 11: 16–23.
28.
AntmanK.S., ArmitageJ.O., HorowitzM.M.Autotransplants for breast cancer in North America. Proc Annu Meet Am Soc Clin Oncol.1994; 13: A69.
29.
HortobagyiG.N.High-dose chemotherapy is not an established treatment for breast cancer. ASCO Educational Book.1995; 341–346.
30.
FalksonG., HolcroftC., GelmanR.S.Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol.1995; 13: 1453–1458.
31.
BezwodaW.R., SeymourL., DanseyR.D.High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer; a randomized trial. J Clin Oncol.1995; 13: 2483–2489.
32.
PetersW.P., JonesR.B., VredenburghJ.A large, prospective, randomized trial of high-dose combination alkylating agents with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A149.
33.
MansourE.G., GrayR., ShatilaA.H.Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med.1989; 320: 485–490.
34.
FisherB., RedmondC., DimitrovN.V.A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med.1989; 320: 473–478.
35.
Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer.The Ludwig Breast Cancer Study Group. N Engl J Med.1989; 320: 491–496.
36.
MussH.B., ThorA.D., BerryD.A.c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med.1994; 330: 1260–1266.
37.
RosnerD., LaneW.W.Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. Cancer.1991; 68: 1482–1494.
38.
Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer.“Nolvadex” Adjuvant Trial Organisation. Br J Cancer.1988; 57: 608–611.
39.
Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial.Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet.1987; 2: 171–175.
40.
FisherB., CostantinoJ., RedmondC.A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med.1989; 320: 479–484.
41.
HortonJ.1995 Oxford breast cancer overview: preliminary outcomes. Cancer Control: JMCC.1996; 3: 78–79.
42.
FisherB., DignamJ., WieandS.Duration of tamoxifen (TAM) therapy for primary breast cancer: 5 vs 10 years (NSABP B-14). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A118.
43.
Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer.Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst.1996; 88: 1543–1549.
44.
TormeyD.C., GrayR., FalksonH.C.Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst.1996; 88: 1828–1833.
45.
PetoR., CollinsR., GrayR.Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol.1995; 48: 23–40.
46.
SwainS.Tamoxifen: the long and short of it. J Natl Cancer Inst.1996; 88: 1510–1512.
47.
FisherB., RedmondC., Legault-PoissonS.Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol.1990; 8: 1005.
48.
WilsJ., BlissJ.M., CoombesR.C.A multicenter randomized trial of tamoxifen versus tamoxifen plus epirubicin in postmenopausal women with node-positive breast cancer. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A101.
49.
NamerM., FumoleauP., DevauxE.Node positive postmenopausal breast cancer patients: six-year follow-up results of a randomized trial testing the role of hormonotherapy (HT) chemotherapy (CT) or combination. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A78.
50.
MakrisA., PowlesT.J., AshleyS.E.A randomized trial of neoadjuvant chemoendocrine therapy in operable breast cancer. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A51.
51.
CummingsF.J., GrayR., TormeyD.C.Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol.1993; 11: 29–35.
